CA2888805C - Methods and compositions for promoting axon regeneration and nerve function - Google Patents

Methods and compositions for promoting axon regeneration and nerve function Download PDF

Info

Publication number
CA2888805C
CA2888805C CA2888805A CA2888805A CA2888805C CA 2888805 C CA2888805 C CA 2888805C CA 2888805 A CA2888805 A CA 2888805A CA 2888805 A CA2888805 A CA 2888805A CA 2888805 C CA2888805 C CA 2888805C
Authority
CA
Canada
Prior art keywords
nec
related compound
neuron
inhibitor
necrostatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2888805A
Other languages
English (en)
French (fr)
Other versions
CA2888805A1 (en
Inventor
Demetrios Vavvas
Joan W. Miller
Larry Benowitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Massachusetts Eye and Ear Infirmary
Original Assignee
Boston Children's Hospital
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2888805(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boston Children's Hospital, Massachusetts Eye and Ear Infirmary filed Critical Boston Children's Hospital
Publication of CA2888805A1 publication Critical patent/CA2888805A1/en
Application granted granted Critical
Publication of CA2888805C publication Critical patent/CA2888805C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2888805A 2011-10-21 2012-10-22 Methods and compositions for promoting axon regeneration and nerve function Expired - Fee Related CA2888805C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550191P 2011-10-21 2011-10-21
US61/550,191 2011-10-21
PCT/US2012/061324 WO2013059791A2 (en) 2011-10-21 2012-10-22 Methods and compositions for promoting axon regeneration and nerve function

Publications (2)

Publication Number Publication Date
CA2888805A1 CA2888805A1 (en) 2013-04-25
CA2888805C true CA2888805C (en) 2020-07-14

Family

ID=47116494

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2888805A Expired - Fee Related CA2888805C (en) 2011-10-21 2012-10-22 Methods and compositions for promoting axon regeneration and nerve function

Country Status (6)

Country Link
US (3) US20140357570A1 (enExample)
EP (1) EP2773341A2 (enExample)
JP (3) JP6254090B2 (enExample)
CA (1) CA2888805C (enExample)
HK (1) HK1203044A1 (enExample)
WO (1) WO2013059791A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749634C1 (ru) * 2020-11-30 2021-06-16 Федеральное государственное бюджетное учреждение "Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова" Министерства здравоохранения Российской Федерации Способ моделирования лечения больных с двигательными и висцеральными расстройствами на лабораторных животных.

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137642A1 (en) 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US20140024598A1 (en) 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
EP2773341A2 (en) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
TWI648274B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類 （二）
CL2013003785A1 (es) * 2013-12-30 2014-07-11 Univ Pontificia Catolica Chile Uso de necrostatina-1 para el tratamiento de la degeneracion axonal inducida por daños agudos y cronicos
WO2016094846A1 (en) * 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
EP3265440A1 (en) 2015-03-06 2018-01-10 Concert Pharmaceuticals Inc. Deuterated emricasan
RU2716136C2 (ru) 2015-07-02 2020-03-06 Ф. Хоффманн-Ля Рош Аг Бициклические лактамы и способы их применения
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
JP7349359B2 (ja) 2016-10-17 2023-09-22 エフ． ホフマン－ラ ロシュ アーゲー 二環式ピリドンラクタム及びその使用方法。
LT3552017T (lt) 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
SG11202006304SA (en) * 2017-12-31 2020-07-29 Evergreen Biosciences Compositions for cryopreservation and methods of use thereof
EP3781571B1 (en) 2018-04-20 2024-01-17 F. Hoffmann-La Roche AG N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
KR20250119466A (ko) * 2024-01-31 2025-08-07 (주)노보메디슨 캐스파제 저해제의 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
DE69739105D1 (de) 1996-11-20 2008-12-24 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
JP2002534139A (ja) 1999-01-05 2002-10-15 マサチューセッツ・アイ・アンド・イア・インファーマリー 網膜と脈絡膜への経強膜徐放性薬剤標的送達
WO2001028493A2 (en) * 1999-10-15 2001-04-26 President And Fellows Of Harvard College Small molecule inhibitors of necrosis
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
TR200201047T2 (tr) 1999-10-21 2002-07-22 Alcon, Inc. İlaç verme vasıtası.
AU1920501A (en) 1999-12-03 2001-06-12 Alcon Universal Limited The use of caspase 9 inhibitors to treat ocular neural pathology
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US20030103945A1 (en) * 2001-02-09 2003-06-05 Chen Dong Feng Methods and compositions for stimulating axon regeneration and preventing neuronal cell degeneration
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
WO2003061519A2 (en) 2002-01-18 2003-07-31 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20050130877A1 (en) * 2003-03-14 2005-06-16 Children's Medical Center Corporation Axon regeneration with PKC inhibitors
AU2004315596B2 (en) * 2003-08-29 2011-11-24 President And Fellows Of Harvard College Inhibitors of cellular necrosis
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
US20070298129A1 (en) 2005-08-24 2007-12-27 Neurotech Pharmaceuticals Co., Ltd. Compounds and compositions for treating neuronal death or neurological dysfunction
US20070049565A1 (en) * 2005-08-24 2007-03-01 Neurotech Pharmaceuticals Co., Ltd. Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
CA2633500A1 (en) * 2005-12-20 2007-07-05 President And Fellows Of Harvard College Compounds, screens, and methods of treatment
CN102408470A (zh) 2005-12-23 2012-04-11 洛桑大学 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽
JP5366812B2 (ja) * 2006-10-10 2013-12-11 プレジデント アンド フェロウズ オブ ハーバード カレッジ 化合物、スクリーニング、および治療方法
US20090022570A1 (en) * 2007-07-16 2009-01-22 Joe David Craig System, method and apparatus for feeding biomass into a pressurized vessel
CA2696349A1 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Heterocyclic inhibitors of necroptosis
JP2012500283A (ja) * 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク． （ｒ）−プラミペキソールを使用した組成物並びにその方法
WO2010075290A1 (en) 2008-12-22 2010-07-01 President And Fellows Of Harvard College Unsaturated heterocyclic inhibitors of necroptosis
US7622106B1 (en) 2009-03-06 2009-11-24 Board Of Regents, The University Of Texas System Necrosis assay
JP5723294B2 (ja) 2009-12-09 2015-05-27 北海道公立大学法人 札幌医科大学 スーパーオキシド製造方法、スーパーオキシド消去能評価方法、スーパーオキシド製造装置およびスーパーオキシド消去能評価装置
US20130137642A1 (en) 2010-04-23 2013-05-30 Demetrios Vavvas Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
US20140024598A1 (en) 2010-11-01 2014-01-23 Demetrios Vavvas Methods and compositions for preserving retinal ganglion cells
EP2773341A2 (en) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749634C1 (ru) * 2020-11-30 2021-06-16 Федеральное государственное бюджетное учреждение "Российский научный центр радиологии и хирургических технологий имени академика А.М. Гранова" Министерства здравоохранения Российской Федерации Способ моделирования лечения больных с двигательными и висцеральными расстройствами на лабораторных животных.

Also Published As

Publication number Publication date
JP2014530881A (ja) 2014-11-20
JP2018065838A (ja) 2018-04-26
JP6861764B2 (ja) 2021-04-21
HK1203044A1 (en) 2015-10-16
US20140357570A1 (en) 2014-12-04
WO2013059791A3 (en) 2013-07-11
WO2013059791A2 (en) 2013-04-25
CA2888805A1 (en) 2013-04-25
JP6254090B2 (ja) 2017-12-27
US20190117724A1 (en) 2019-04-25
JP6560325B2 (ja) 2019-08-14
EP2773341A2 (en) 2014-09-10
US10022419B2 (en) 2018-07-17
US10799552B2 (en) 2020-10-13
JP2019196381A (ja) 2019-11-14
US20160151442A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
US10799552B2 (en) Methods for treating diabetic neurotherapy
JP7571171B2 (ja) 翼状片を治療するための組成物及び方法
US10617735B2 (en) Methods and compositions for preserving retinal ganglion cells
AU2017202550B2 (en) Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
JP5232678B2 (ja) 新形成細胞の細胞消滅死を誘導する方法
ES2549955T3 (es) Prevención de hipoglucemia en pacientes con diabetes mellitus de tipo 2
KR20120129904A (ko) 안내 혈관 신생 및/또는 안내 혈관 투과성 항진을 수반하는 질환의 예방 또는 치료를 위한 의약
KR20100016140A (ko) 가령 황반 변성의 예방 또는 치료제
CA3056878C (en) Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
JP2015521608A (ja) 緑内障および他の変性眼疾患のヒトにおける失明の治療のためのインターバル療法
TWI791440B (zh) Dsg2-衍生肽
ES3064694T3 (en) Gap junction modulators and their use for the treatment of age-related macular degeneration
US11497793B2 (en) Compositions and methods for treating glioblastoma
KR20210058586A (ko) 실데나필 및 rock 저해제를 포함하는 뇌졸중 치료용 약학적 조성물
ES3062815T3 (en) Compositions for treating aging-associated impairments using ccr3-inhibitors
HK40069641A (en) Compositions and methods for treating pterygium
HK1143544A (en) The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
HK1256602B (en) Compositions and methods for treating pterygium

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171013

MKLA Lapsed

Effective date: 20221024